Immuneering Corp Market Cap ($237.62 Million)
Market Cap & Net Worth: Immuneering Corp (IMRX)
Immuneering Corp market cap. Immuneering Corp (NASDAQ:IMRX) has a market capitalization of $237.62 Million ($237.62 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15653 globally and #3734 in its home market, demonstrating a -0.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immuneering Corp's stock price $3.68 by its total outstanding shares 64569967 (64.57 Million). Also see IMRX cash flow conversion for how efficiently the company converts equity into cash flow.
Immuneering Corp Market Cap History (2021–2026)
Immuneering Corp market cap history from 2021 to 2026. Data shows change from $1.04 Billion to $237.62 Million (-25.70% CAGR). Check IMRX share price today for real-time trading data and today's change.
Index Memberships
Immuneering Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #420 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1533 of 3165 |
Weight: Immuneering Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immuneering Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immuneering Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMRX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1043053.31x
Immuneering Corp's market cap is 1043053.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.04 Billion | $2.08 Million | -$33.54 Million | 501.98x | N/A |
| 2022 | $313.16 Million | $316.95K | -$50.51 Million | 988.05x | N/A |
| 2023 | $474.59 Million | $455.00 | -$53.47 Million | 1043053.31x | N/A |
Competitor Companies of IMRX by Market Capitalization
Companies near Immuneering Corp in the global market cap rankings as of November 4, 2026. Also see Immuneering Corp asset portfolio for a full breakdown of the balance sheet.
Key companies related to Immuneering Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Immuneering Corp (2021–2026)
Market capitalization of Immuneering Corp from 2021 to today. Between 2021 and today, Immuneering Corp's market cap moved from $1.04 Billion to $ 237.62 Million, with a yearly change of -25.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $237.62 Million | -44.07% |
| 2025 | $424.87 Million | +199.09% |
| 2024 | $142.05 Million | -70.07% |
| 2023 | $474.59 Million | +51.55% |
| 2022 | $313.16 Million | -70.01% |
| 2021 | $1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Immuneering Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $237.62 Million USD |
| MoneyControl | $237.62 Million USD |
| MarketWatch | $237.62 Million USD |
| marketcap.company | $237.62 Million USD |
| Reuters | $237.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more